Loading...
Loading...
AMAM| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.1M |
| Operating Expense | 25.7M |
| Operating I/L | -25.6M |
| Other Income/Expense | -0.1M |
| Interest Income | 2.9M |
| Pretax | -22.8M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -23.0M |
Ambrx Biopharma Inc. is a clinical-stage biologics company specializing in engineered precision biologics using its proprietary expanded genetic code technology platform. The company's lead product candidate, ARX788, is an anti-HER2 antibody-drug conjugate (ADC) being investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors. Additionally, Ambrx is developing two earlier-stage product candidates, ARX517 and ARX305, as well as multiple product candidates targeting immuno-oncology applications, including ARX822 and ARX102. The company generates revenue through collaborations with pharmaceutical and biotech companies for the development and commercialization of its product candidates.
